Nuvation Bio Inc. (NYSE:NUVB – Free Report) – Equities research analysts at HC Wainwright lowered their FY2026 EPS estimates for Nuvation Bio in a report issued on Thursday, November 5th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.34) per share for the year, down from their previous forecast of ($0.33). HC Wainwright has a “Buy” rating and a $21.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.13) EPS.
Several other research firms have also issued reports on NUVB. Royal Bank Of Canada reduced their price target on Nuvation Bio from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a research report on Wednesday, September 16th. Cantor Fitzgerald started coverage on Nuvation Bio in a research note on Friday, August 21st. They set an “overweight” rating for the company. Citizens Jmp restated a “market outperform” rating and issued a $10.00 target price on shares of Nuvation Bio in a report on Wednesday, September 16th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a research note on Monday, October 19th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.89.
Read Our Latest Stock Report on NUVB
Nuvation Bio Trading Up 4.4%
NYSE NUVB opened at $4.34 on Monday. The firm has a market cap of $1.53 billion, a PE ratio of -10.86 and a beta of 1.73. Nuvation Bio has a 1-year low of $3.97 and a 1-year high of $9.75. The stock has a 50-day moving average of $5.34 and a 200-day moving average of $5.36. The company has a current ratio of 8.37, a quick ratio of 8.14 and a debt-to-equity ratio of 0.96.
Nuvation Bio (NYSE:NUVB – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). The firm had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $34.39 million. Nuvation Bio had a negative return on equity of 43.15% and a negative net margin of 67.38%.
Institutional Investors Weigh In On Nuvation Bio
Institutional investors and hedge funds have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership grew its position in shares of Nuvation Bio by 75.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,439,357 shares of the company’s stock worth $6,175,000 after buying an additional 619,725 shares during the last quarter. NewEdge Advisors LLC raised its holdings in shares of Nuvation Bio by 19.5% during the second quarter. NewEdge Advisors LLC now owns 1,231,733 shares of the company’s stock valued at $6,996,000 after acquiring an additional 200,621 shares in the last quarter. Tanaka Capital Management Inc. lifted its stake in Nuvation Bio by 7.2% in the first quarter. Tanaka Capital Management Inc. now owns 901,825 shares of the company’s stock worth $3,869,000 after acquiring an additional 60,220 shares during the period. Wellington Management Group LLP lifted its stake in Nuvation Bio by 6.5% in the second quarter. Wellington Management Group LLP now owns 715,781 shares of the company’s stock worth $4,066,000 after acquiring an additional 43,637 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Nuvation Bio in the second quarter valued at $3,804,000. Hedge funds and other institutional investors own 61.67% of the company’s stock.
Insider Activity
In related news, insider Gary Hattersley sold 100,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the transaction, the insider owned 100,000 shares in the company, valued at $709,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 30.11% of the stock is owned by insiders.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer.
Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.
The company conducts clinical development internationally and markets Ibtrozi in the United States.
Read More
- Five stocks we like better than Nuvation Bio
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
